Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Total Liabilities (2020 - 2025)

Rapid Micro Biosystems' Total Liabilities history spans 6 years, with the latest figure at $41.6 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 82.52% to $41.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.6 million, a 82.52% increase, with the full-year FY2025 number at $41.6 million, up 82.52% from a year prior.
  • Total Liabilities hit $41.6 million in Q4 2025 for Rapid Micro Biosystems, up from $40.1 million in the prior quarter.
  • Over the last five years, Total Liabilities for RPID hit a ceiling of $151.0 million in Q1 2021 and a floor of $19.7 million in Q3 2021.
  • Historically, Total Liabilities has averaged $32.2 million across 5 years, with a median of $22.4 million in 2023.
  • Biggest five-year swings in Total Liabilities: crashed 84.78% in 2022 and later skyrocketed 86.66% in 2025.
  • Tracing RPID's Total Liabilities over 5 years: stood at $20.2 million in 2021, then soared by 31.17% to $26.5 million in 2022, then dropped by 3.84% to $25.5 million in 2023, then dropped by 10.39% to $22.8 million in 2024, then surged by 82.52% to $41.6 million in 2025.
  • Business Quant data shows Total Liabilities for RPID at $41.6 million in Q4 2025, $40.1 million in Q3 2025, and $21.0 million in Q2 2025.